Toth Financial Advisory’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Toth Financial Advisory’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,000	Closed	-$15K	–	836
2021 Q3	$15K	Hold	3,000	–	–	﹤0.01%	434
2021 Q2	$20K	Hold	3,000	–	–	﹤0.01%	380
2021 Q1	$21K	Hold	3,000	–	–	﹤0.01%	380
2020 Q4	$19K	Buy	+3,000	New	+$17.7K	﹤0.01%	353

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Toth Financial Advisory's PRTK Position: Q4 2021 in Review

Toth Financial Advisory sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2021, closing a stake of 3,000 shares — an estimated $15K sold.

Toth Financial Advisory first reported a position in PRTK in Q4 2020 and held it in 4 quarters. The position peaked at $21K in Q1 2021. 103 funds tracked by Wall St. Rank hold PRTK as of Q4 2021.

Toth Financial Advisory reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Toth Financial Advisory sold 3,000 Paratek Pharmaceuticals, Inc. shares in Q4 2021, an estimated $15K.
Toth Financial Advisory first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 4 quarters.
Toth Financial Advisory's Paratek Pharmaceuticals, Inc. position peaked at $21K in Q1 2021.
103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2021.

Based on Toth Financial Advisory's 13F filing for Q4 2021, filed 31 Jan 2022.